Historical valuation data is not available at this time.
Arvinas, Inc. (ARVN) is a clinical-stage biopharmaceutical company pioneering targeted protein degradation (TPD) therapeutics. The company leverages its proprietary PROTAC® (PROteolysis TArgeting Chimera) platform to develop novel small-molecule drugs that selectively degrade disease-causing proteins, addressing challenges in oncology and neurodegenerative diseases. Arvinas holds a first-mover advantage in the TPD space, with lead candidates ARV-471 (for breast cancer) and ARV-110 (for prostate cancer) in Phase 2 trials. Its collaboration with Pfizer (for ARV-471) and strategic partnerships with Bayer and Genentech validate its technology and provide non-dilutive funding.
PROTAC® platform with 100+ patents; potential to target 'undruggable' proteins; pipeline includes 5 disclosed programs (2 clinical, 3 preclinical).
Arvinas presents high-risk/high-reward potential as a TPD leader with validated science and deep-pocketed partners. Near-term upside hinges on positive ARV-471 data, which could trigger partnership milestones and investor enthusiasm. However, clinical failures or delays would severely impact the stock given its $2.5B market cap and lack of revenue diversification. Suitable for speculative biotech investors with a 3-5 year horizon.
Arvinas SEC filings (10-K, 10-Q), company presentations, Nature Reviews Drug Discovery (2022), EvaluatePharma.